HK Stock Market Move | EPIWORLD (02726) rises nearly 7%, expects FY2026 net profit to grow about 800% to 1,217% year-on-year, plans to repurchase no more than HK$1.78 billion of H shares.
EPIWORLD (02726) rose nearly 7%. As of press time, it was up 6.77% at HK$82.85, with turnover of HK$3.1083 million.
EPIWORLD (02726) rises nearly 7%, up 6.77% as of press time at HK$82.85, with turnover of HK$3.1083 million.
On the news front, on November 2, EPIWORLD issued a positive profit alert. The group expects to record the following financial performance for the year ending December 31, 2026 (FY2026): revenue is expected to be approximately RMB1.607 billion to RMB1.76 billion, up about 110% to 130% year-on-year; net profit is expected to be approximately RMB108 million to RMB158 million, up about 800% to 1,217% year-on-year; adjusted net profit is expected to be approximately RMB281 million to RMB331 million, up about 42% to 67% year-on-year. The board believes the expected changes in performance are mainly attributable to: growth in downstream application demand for AI data centers, which drove an increase in orders and sales of the group's silicon carbide epitaxial wafers, among other factors.
In addition, EPIWORLD announced that the board has resolved and approved the company to repurchase H shares on the Stock Exchange's open market from time to time. Under the repurchase mandate, the company may repurchase no more than 10% of the total number of the company's issued and fully paid H shares (excluding treasury shares (if any)) as of the date the repurchase mandate was approved, i.e. no more than 11.892 million H shares. The total amount of funds proposed to be used for such repurchases shall not exceed HK$1.78 billion.
Related Articles

HK Stock Market Move | SIMCERE PHARMA (02096) rises over 2% as it further enters into a collaboration with Lynk Pharmaceuticals on the selective JAK1 inhibitor zepuzetinib

HK Stock Market Move | SF INTRA-CITY (09699) rose more than 7% in morning trading; recently renewed a cooperation framework agreement with S.F. Holding, locking in a three-year long-term partnership.

AbbVie (ABBV.US) Expands UK Oxford R&D Facility, Betting on Innovation in Immunology, Neuroscience, and Oncology Drugs
HK Stock Market Move | SIMCERE PHARMA (02096) rises over 2% as it further enters into a collaboration with Lynk Pharmaceuticals on the selective JAK1 inhibitor zepuzetinib

HK Stock Market Move | SF INTRA-CITY (09699) rose more than 7% in morning trading; recently renewed a cooperation framework agreement with S.F. Holding, locking in a three-year long-term partnership.

AbbVie (ABBV.US) Expands UK Oxford R&D Facility, Betting on Innovation in Immunology, Neuroscience, and Oncology Drugs






